Redwood City, California – July 11, 2017 – Synthego, a leading provider of genome engineering solutions, announces the CRISPR Pioneers Program to help new CRISPR users conduct genome engineering research by reducing impediments to achieving consistent high quality results. The Program, which includes access to a powerful CRISPR design tool, free world-class synthetic reagents, scientific support and online resources, was built with new CRISPR users in mind. However, existing researchers can also benefit from access to the latest generation of CRISPR technologies and tools to achieve consistent, high efficiency CRISPR experiments.
With the gene editing market growing rapidly and projected to exceed billion by 2025, a new generation of genome engineering researchers will enter the market in coming years. A recent survey on the Future of CRISPR found that 87 percent of first-time CRISPR users are also new to gene editing. As a result, new users will face many challenges when performing their first CRISPR gene editing experiment. These challenges include knowing where to start, acquiring domain expertise to design a CRISPR guide, procuring high quality reagents such as synthetic single guide RNAs, and gaining access to scientific support. Hence, new researchers require improved tools and resources to successfully conduct CRISPR gene editing experiments.
Current CRISPR users, on the other hand, may also experience challenges when trying to conduct successful CRISPR gene editing experiments. One common source of frustration is the inability to consistently achieve high editing efficiencies in order to have a predictable and efficient scientific workflow. To achieve high editing efficiencies, a significant amount of time is required during guide design, and construction and cloning of guide RNAs. For example, the time required to design and create a single CRISPR guide can take more than a week depending on the method. For these users, the CRISPR Pioneers Program offers significant time savings and experimental consistency with its unique gene knockout design tool, and high efficiency synthetic guide RNA.
CRISPR Pioneers Program includes:
CRISPR Design Tool with 100,000 genomes, instant knockout recommendations yielding quality designs within minutes
Synthetic sgRNA enabling up to 90 percent editing efficiency that is 100 percent DNA-free with fast turnaround
Scientific Support including an online help center and technical support
CRISPR Resources such as eBooks, protocols, and a CRISPR quick-start guide
"While CRISPR has significantly reduced the complexity of genome engineering, conducting successful CRISPR gene editing experiments can still be very difficult for the new researcher," said Ted Tisch, COO at Synthego. "Synthego is focused on simplifying the workflow for CRISPR, and with the CRISPR Pioneers Program, Synthego aims to help a new generation of researchers by making it much easier to perform CRISPR experiments for scientific research and discovery."
Synthego is working with numerous industry collaborators worldwide to optimize CRISPR genome engineering research with the latest technologies and tools. By compiling this experience and associated technologies into the CRISPR Pioneers Program, Synthego strives to help the broader scientific community adopt CRISPR as a powerful and effective genome editing tool.
To sign up for the free CRISPR Pioneers Program, visit: www.synthego.com/pioneers.
For more information on Synthego, visit: www.synthego.com.
Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions alongside an expanding molecular and clinical diagnostics portfolio with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models, custom manufacturing capabilities and exceptional technical expertise, Synthego empowers researchers and therapeutic developers to unlock better patient outcomes by advancing discovery, diagnostics, and the next generation of advanced therapies.
Greg Huegerich
VP, Marketing
[email protected]